Adaptimmune Therapeutics PLC (ADAP) Given “Buy” Rating at SunTrust Banks, Inc.

SunTrust Banks, Inc. reaffirmed their buy rating on shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) in a research report sent to investors on Friday morning. SunTrust Banks, Inc. currently has a $10.00 price target on the biotechnology company’s stock.

Several other brokerages have also recently commented on ADAP. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a sell rating to a hold rating in a report on Friday, August 25th. Zacks Investment Research cut shares of Adaptimmune Therapeutics PLC from a buy rating to a hold rating in a report on Friday. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a strong sell rating to a sell rating in a report on Thursday, July 20th. TheStreet raised shares of Adaptimmune Therapeutics PLC from a d rating to a c rating in a report on Thursday, November 2nd. Finally, Leerink Swann reaffirmed an outperform rating and set a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. Adaptimmune Therapeutics PLC presently has a consensus rating of Hold and an average price target of $11.58.

Shares of Adaptimmune Therapeutics PLC (ADAP) traded up $0.02 on Friday, hitting $8.10. 148,300 shares of the stock traded hands, compared to its average volume of 259,473. Adaptimmune Therapeutics PLC has a 12 month low of $3.76 and a 12 month high of $9.29.

ILLEGAL ACTIVITY WARNING: This article was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://stocknewstimes.com/2017/11/11/adaptimmune-therapeutics-plc-adap-given-buy-rating-at-suntrust-banks-inc.html.

Several hedge funds and other institutional investors have recently bought and sold shares of ADAP. KCG Holdings Inc. acquired a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter worth approximately $133,000. OxFORD Asset Management LLP acquired a new stake in shares of Adaptimmune Therapeutics PLC during the 2nd quarter worth approximately $156,000. Paloma Partners Management Co acquired a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter worth approximately $165,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Adaptimmune Therapeutics PLC during the 3rd quarter worth approximately $199,000. Finally, Virtu KCG Holdings LLC boosted its position in shares of Adaptimmune Therapeutics PLC by 108.0% during the 2nd quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 26,105 shares in the last quarter. Institutional investors and hedge funds own 68.12% of the company’s stock.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply